Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
NCT ID NCT07662525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial investigates whether combining atorvastatin (a cholesterol-lowering drug), N-acetyl-L-cysteine (an antioxidant), and romiplostim (a platelet-boosting drug) can help adults with immune thrombocytopenia (ITP) who no longer respond to steroids. The goal is to see if this approach can keep platelet counts stable even after stopping all treatments. Fifty participants will receive the combination for 24 weeks, followed by a gradual taper of romiplostim, and will be monitored for sustained response off-treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atorvastatin, N-acetyl-L-cysteine, and romiplostim
What this could lead to
If successful, this combination could help people with hard-to-treat immune thrombocytopenia maintain safe platelet levels without needing long-term medication.
What could go wrong
This is a small, single-center study with no control group, so results may not apply broadly. The treatment involves multiple drugs and close monitoring, and some participants may not respond or may experience side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China